IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Expression of ER-alpha 36, a Novel Variant of Estrogen Receptor alpha, and Resistance to Tamoxifen Treatment in Breast Cancer
Shi, Liang; Dong, Bin; Li, Zhongwu; Lu, Yunwei; Tao Ouyang; Li, Jinfeng; Wang, Tianfeng; Fan, Zhaoqing; Fan, Tie; Lin, Benyao; Wang, Zhaoyi; Xie, Yuntao1
刊名JOURNAL OF CLINICAL ONCOLOGY
2009-07-20
DOI10.1200/JCO.2008.17.2254
27期:21页:3423-3429
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]ENDOCRINE THERAPY ; GROWTH ; ASSOCIATION ; MECHANISMS ; STRATEGIES ; ONCOGENE ; CELLS ; HER-2 ; ASSAY
英文摘要

Purpose Recently, a 36-kDa variant of estrogen receptor alpha (ER-alpha 66), ER-alpha 36, has been identified and cloned. ER-alpha 36 predominantly localizes on the plasma membrane and in the cytoplasm and mediates a membrane-initiated "nongenomic" signaling pathway. Here, we investigate the association between ER-alpha 36 expression and tamoxifen resistance in patients with breast cancer.

Patients and Methods ER-alpha 36 protein expression in tumors from 896 women (two independent cohorts, 1 and 2) with operable primary breast cancer was assessed using an immunohistochemistry assay.

Results In the first cohort of 710 consecutive patients, overexpression of ER-alpha 36 was associated with poorer disease-free survival (DFS) and disease-specific survival (DSS) in patients with ER-alpha 66 positive tumors who received tamoxifen treatment (chemotherapy plus tamoxifen or tamoxifen alone, n = 307). In contrast, ER-alpha 36 was not associated with survival in patients with ER-alpha 66 positive tumors who did not receive tamoxifen (chemotherapy alone, n = 129) and in patients with ER-alpha 66-negative tumors whether they received tamoxifen (n = 73) or not (n = 149). In the second cohort of 186 patients who only received tamoxifen as adjuvant therapy, overexpression of ER-alpha 36 was significantly associated with poorer DFS and DSS in 156 ER-alpha 66-positive patients from this cohort, and ER-alpha 36 remained an independent unfavorable factor for both DFS and DSS in these 156 patients by a multivariate analysis (DFS: hazard ratio [HR] = 5.47; 95% CI, 1.81 to 16.51; P = .003; DSS: HR = 13.97; 95% CI, 1.58 to 123.53; P = .018).

Conclusion Women with ER-alpha 66-positive tumors that also express high levels of ER-alpha 36 are less likely to benefit from tamoxifen treatment.

语种英语
WOS记录号WOS:000268049100005
项目编号985-2-067-113 ; 30672419 ; DK070016 ; BCTR81906 ; LB-595
资助机构Program for New Century Excellent Talents in University ; National Natural Science Foundation of China ; National Institutes of Health ; Susan G. Komen Breast Cancer Foundation ; Nebraska Tobacco Settlement Biomedical Research Program Award
引用统计
被引频次:118[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/59782
专题北京大学临床肿瘤学院
作者单位1.Creighton Univ, Sch Med, Dept Surg, Omaha, NE 68178 USA
2.Creighton Univ, Sch Med, Dept Pathol, Omaha, NE 68178 USA
3.Peking Univ, Sch Oncol, Breast Ctr,Minist Edu, Beijing Canc Hosp & Inst,Key Lab Carcinogenesis &, Beijing 100036, Peoples R China
4.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Pathol, Beijing 100036, Peoples R China
推荐引用方式
GB/T 7714
Shi, Liang,Dong, Bin,Li, Zhongwu,et al. Expression of ER-alpha 36, a Novel Variant of Estrogen Receptor alpha, and Resistance to Tamoxifen Treatment in Breast Cancer[J]. JOURNAL OF CLINICAL ONCOLOGY,2009,27(21):3423-3429.
APA Shi, Liang.,Dong, Bin.,Li, Zhongwu.,Lu, Yunwei.,Tao Ouyang.,...&Xie, Yuntao.(2009).Expression of ER-alpha 36, a Novel Variant of Estrogen Receptor alpha, and Resistance to Tamoxifen Treatment in Breast Cancer.JOURNAL OF CLINICAL ONCOLOGY,27(21),3423-3429.
MLA Shi, Liang,et al."Expression of ER-alpha 36, a Novel Variant of Estrogen Receptor alpha, and Resistance to Tamoxifen Treatment in Breast Cancer".JOURNAL OF CLINICAL ONCOLOGY 27.21(2009):3423-3429.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Shi, Liang]的文章
[Dong, Bin]的文章
[Li, Zhongwu]的文章
百度学术
百度学术中相似的文章
[Shi, Liang]的文章
[Dong, Bin]的文章
[Li, Zhongwu]的文章
必应学术
必应学术中相似的文章
[Shi, Liang]的文章
[Dong, Bin]的文章
[Li, Zhongwu]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。